Vyant Bio, Inc. is a biotechnology company focused on drug discovery for complex neurodevelopmental and neurodegenerative disorders. The Company is engaged in combining sophisticated data science capabilities with highly functional human cell derived disease models. Its central nervous system (CNS) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. The Company’s platform is designed to elucidate disease pathophysiology; formulate key therapeutic hypotheses; identify and validate drug targets, cellular assays, and biomarkers to guide candidate molecule selection, and guide clinical trial patient selection and trial design. The Company’s programs are focused on identifying repurposed and novel small molecule clinical candidates for rare CNS genetic disorders, including Rett Syndrome (Rett), CDKL5 Deficiency Disorders (CDD) and familial Parkinson’s Disease (PD).